Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
about
Oxidative stress in schizophreniaAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionViral infection, inflammation and schizophreniaAntioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.Meta-analysis of oxidative stress in schizophrenia.Electrophysiological intermediate biomarkers for oxidative stress in schizophreniaReduced antioxidant defense in early onset first-episode psychosis: a case-control study.Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients.Oxidative stress in schizophrenia: an integrated approach.Oxidative stress and level of antioxidant enzymes in drug-naive schizophrenics.Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism.No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia.Amelioration of the haloperidol-induced memory impairment and brain oxidative stress by cinnarizine.Evaluation of antioxidant deficit in schizophreniaα-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death.Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y neuroblastoma cells.Neuroprotection in Schizophrenia and Its Therapeutic Implications.Paliperidone regulates intracellular redox system in rat brain: Role of purine mechanism.Evaluation of Oxidative Status in Patients Treated with Electroconvulsive Therapy.Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro.Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model.Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research.The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.Effects of antipsychotics and vitamin C on the formation of reactive oxygen species.Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro.A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia.Thiol Disulfide Homeostasis in Schizophrenic Patients Using Atypical Antipsychotic Drugs.Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility
P2860
Q24595660-2C9002AA-30BE-4B08-88D8-83030B176BB0Q30386608-DDC45E1F-B477-4494-AFD3-FD19A7557138Q30440507-721463D5-0A6E-4D49-868C-F8764DCC26E5Q33350202-897638BE-E341-464A-9445-DE34A2E0CAEBQ33601360-B5170947-3E77-4662-B54E-3FDC5816CF4CQ33647885-4043DF68-2B7D-4E8F-9B0B-3575FF4EB0D4Q33820188-FF74FFD2-4FD5-46EB-ACFF-4B870E87B9C0Q33979025-5AB524A9-9402-41D8-9A17-2C3C45646B09Q34494844-F0E1238B-15A4-4E9D-BD08-5119497964B3Q34786239-583E2812-5D8B-4463-9F38-444A7BD05268Q34837403-2834A93A-B912-40A1-9112-E12CC73EB59DQ36756178-4093F113-56EA-4CF6-9956-679CE2D9381EQ37172823-264E7053-EF12-40BD-AB6A-2C33A06D4E08Q37351067-96DF65E5-C253-4E52-8060-8732A383AB70Q39279185-1CABDE5B-1FCC-4B14-8E6E-AB4F5ED631CCQ39552320-77402B49-99C9-4DAA-A21A-DE80406DFCE0Q39664514-FBB3ED0F-8663-45D2-B865-2F2862D447ABQ41449646-3C165298-8A83-4D59-8563-C71230D11618Q41644149-65315400-3B1A-46BE-B60A-2E99B4B080DBQ42324230-BBED9A03-7958-45D8-B33B-00E74180BDAEQ42745478-0F50BF2A-ADE1-4817-A302-EAC7E8B47598Q43131980-54F634D9-AF39-4717-8921-D0EA973F935FQ43692301-37DFDBAF-35B7-43F4-8362-ABA7D0A26F8CQ45896435-F9E634BB-31B2-4FA5-97F6-8E71BB59E556Q46090406-04800D67-2AE4-4A5A-BB27-5FE1D820E9A3Q46117836-910ECB74-FC7E-4AF8-B379-ECE8013428C5Q48642132-F7BD291B-BD89-4FAB-A64C-A8EF95A5C55CQ49348765-B6AED53E-116D-4FBC-8494-FD57529EBD76Q50507983-F25EAF05-61E0-4C6C-A403-242317A9B3A6Q55887376-165148C0-6126-4451-9316-52CD184DAFBE
P2860
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@en
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@nl
type
label
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@en
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@nl
prefLabel
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@en
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@nl
P2093
P2860
P356
P1433
P1476
Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.
@en
P2093
Anand Saoji
Avinash Turankar
Ganesh Dakhale
Linesh Khobragade
Shruti Khanzode
Suchet Khanzode
P2860
P304
P356
10.1159/000077368
P577
2004-01-01T00:00:00Z